IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis

Caishu Deng, Elzbieta Goluszko, Samuel Baron, Bo Wu, Premkumar Christadoss

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

To study the therapeutic efficacy of IFN-α after the onset of clinical signs of experimental autoimmune myasthenia gravis (EAMG), we treated mice with clinical EAMG with recombinant human IFN-α or mouse IFN-α. In the first experiment, 7 of 16 (44%) mice had a complete clinical remission in the recombinant human IFN-α-treated group, in contrast to none in the placebo group (0/14) (p = 0.006). There was a higher incidence of death and severe disease in the placebo group (7/14) relative to the IFN-α group (4/16). In the second experiment, 6 of 18 (33%) mice in the mouse IFN-α-treated group had a complete clinical remission, while none of 17 (0%) mice in the placebo-treated group had remission (p = 0.011). Again, more mice died or worsened in the placebo group (11/17) compared with the IFN-α group (7/18). IFN-α treatment significantly reduced the anti-acetylcholine receptor (AChR) Ab levels, especially the IgG1 and IgG2b isotypes, and the amount of anti-AChR Abs bound to muscle AChR. IFN-α treatment also lowered CD4 cells in the lymph nodes and spleen, and suppressed the in vitro lymphocyte proliferative response to AChR and its dominant peptide in a dose-dependent manner.

Original languageEnglish (US)
Pages (from-to)5675-5682
Number of pages8
JournalJournal of Immunology
Volume157
Issue number12
StatePublished - Dec 15 1996

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Cholinergic Receptors
Placebos
Therapeutics
Spleen
Immunoglobulin G
Lymph Nodes
Lymphocytes
Muscles
Peptides
Incidence

ASJC Scopus subject areas

  • Immunology

Cite this

Deng, C., Goluszko, E., Baron, S., Wu, B., & Christadoss, P. (1996). IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis. Journal of Immunology, 157(12), 5675-5682.

IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis. / Deng, Caishu; Goluszko, Elzbieta; Baron, Samuel; Wu, Bo; Christadoss, Premkumar.

In: Journal of Immunology, Vol. 157, No. 12, 15.12.1996, p. 5675-5682.

Research output: Contribution to journalArticle

Deng, C, Goluszko, E, Baron, S, Wu, B & Christadoss, P 1996, 'IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis', Journal of Immunology, vol. 157, no. 12, pp. 5675-5682.
Deng C, Goluszko E, Baron S, Wu B, Christadoss P. IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis. Journal of Immunology. 1996 Dec 15;157(12):5675-5682.
Deng, Caishu ; Goluszko, Elzbieta ; Baron, Samuel ; Wu, Bo ; Christadoss, Premkumar. / IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis. In: Journal of Immunology. 1996 ; Vol. 157, No. 12. pp. 5675-5682.
@article{7d42f798d8f6453fbf461618145f2f68,
title = "IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis",
abstract = "To study the therapeutic efficacy of IFN-α after the onset of clinical signs of experimental autoimmune myasthenia gravis (EAMG), we treated mice with clinical EAMG with recombinant human IFN-α or mouse IFN-α. In the first experiment, 7 of 16 (44{\%}) mice had a complete clinical remission in the recombinant human IFN-α-treated group, in contrast to none in the placebo group (0/14) (p = 0.006). There was a higher incidence of death and severe disease in the placebo group (7/14) relative to the IFN-α group (4/16). In the second experiment, 6 of 18 (33{\%}) mice in the mouse IFN-α-treated group had a complete clinical remission, while none of 17 (0{\%}) mice in the placebo-treated group had remission (p = 0.011). Again, more mice died or worsened in the placebo group (11/17) compared with the IFN-α group (7/18). IFN-α treatment significantly reduced the anti-acetylcholine receptor (AChR) Ab levels, especially the IgG1 and IgG2b isotypes, and the amount of anti-AChR Abs bound to muscle AChR. IFN-α treatment also lowered CD4 cells in the lymph nodes and spleen, and suppressed the in vitro lymphocyte proliferative response to AChR and its dominant peptide in a dose-dependent manner.",
author = "Caishu Deng and Elzbieta Goluszko and Samuel Baron and Bo Wu and Premkumar Christadoss",
year = "1996",
month = "12",
day = "15",
language = "English (US)",
volume = "157",
pages = "5675--5682",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - IFN-α Therapy Is Effective in Suppressing the Clinical Experimental Myasthenia Gravis

AU - Deng, Caishu

AU - Goluszko, Elzbieta

AU - Baron, Samuel

AU - Wu, Bo

AU - Christadoss, Premkumar

PY - 1996/12/15

Y1 - 1996/12/15

N2 - To study the therapeutic efficacy of IFN-α after the onset of clinical signs of experimental autoimmune myasthenia gravis (EAMG), we treated mice with clinical EAMG with recombinant human IFN-α or mouse IFN-α. In the first experiment, 7 of 16 (44%) mice had a complete clinical remission in the recombinant human IFN-α-treated group, in contrast to none in the placebo group (0/14) (p = 0.006). There was a higher incidence of death and severe disease in the placebo group (7/14) relative to the IFN-α group (4/16). In the second experiment, 6 of 18 (33%) mice in the mouse IFN-α-treated group had a complete clinical remission, while none of 17 (0%) mice in the placebo-treated group had remission (p = 0.011). Again, more mice died or worsened in the placebo group (11/17) compared with the IFN-α group (7/18). IFN-α treatment significantly reduced the anti-acetylcholine receptor (AChR) Ab levels, especially the IgG1 and IgG2b isotypes, and the amount of anti-AChR Abs bound to muscle AChR. IFN-α treatment also lowered CD4 cells in the lymph nodes and spleen, and suppressed the in vitro lymphocyte proliferative response to AChR and its dominant peptide in a dose-dependent manner.

AB - To study the therapeutic efficacy of IFN-α after the onset of clinical signs of experimental autoimmune myasthenia gravis (EAMG), we treated mice with clinical EAMG with recombinant human IFN-α or mouse IFN-α. In the first experiment, 7 of 16 (44%) mice had a complete clinical remission in the recombinant human IFN-α-treated group, in contrast to none in the placebo group (0/14) (p = 0.006). There was a higher incidence of death and severe disease in the placebo group (7/14) relative to the IFN-α group (4/16). In the second experiment, 6 of 18 (33%) mice in the mouse IFN-α-treated group had a complete clinical remission, while none of 17 (0%) mice in the placebo-treated group had remission (p = 0.011). Again, more mice died or worsened in the placebo group (11/17) compared with the IFN-α group (7/18). IFN-α treatment significantly reduced the anti-acetylcholine receptor (AChR) Ab levels, especially the IgG1 and IgG2b isotypes, and the amount of anti-AChR Abs bound to muscle AChR. IFN-α treatment also lowered CD4 cells in the lymph nodes and spleen, and suppressed the in vitro lymphocyte proliferative response to AChR and its dominant peptide in a dose-dependent manner.

UR - http://www.scopus.com/inward/record.url?scp=0030589245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030589245&partnerID=8YFLogxK

M3 - Article

VL - 157

SP - 5675

EP - 5682

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -